Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate

Pediatrics

Volumn 121, Issue 5, 2008, Pages

  Stacpoole, Peter W ^a,b,c   Gilbert, Lesa R ^a   Neiberger, Richard E ^b   Carney, Paul R ^b   Valenstein, Edward ^b   Theriaque, Douglas W ^b   Shuster, Jonathan J ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Dichloroacetate; Lactic acidosis; Mitochondria; Pyruvate dehydrogenase; Respiratory chain

Indexed keywords

3 HYDROXYBUTYRIC ACID; AMINOTRANSFERASE; DICHLOROACETIC ACID; ELECTROLYTE; GLUCOSE; LACTIC ACID; OXALIC ACID; PLACEBO;

ADOLESCENT; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY HEIGHT; BODY WEIGHT; CARBOHYDRATE DIET; CEREBROSPINAL FLUID ANALYSIS; CHILD; CHILD GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; ELECTROLYTE BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFANT; KIDNEY FUNCTION; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LATENT PERIOD; LEUKOCYTE COUNT; LIVER FUNCTION; LONG TERM CARE; MALE; MEDIAN NERVE; MUSCLE ACTION POTENTIAL; NERVE CONDUCTION; NERVE POTENTIAL; OPEN STUDY; PERONEUS NERVE; PH; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SURAL NERVE; SURVIVAL TIME; TEST MEAL; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; URINARY EXCRETION; BLOOD; KAPLAN MEIER METHOD; METABOLISM; MITOCHONDRIAL ENCEPHALOMYOPATHY; ORAL DRUG ADMINISTRATION; PYRUVATE DEHYDROGENASE COMPLEX DEFICIENCY;

ACIDOSIS, LACTIC; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DICHLOROACETATE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFANT; KAPLAN-MEIERS ESTIMATE; LACTIC ACID; MALE; MITOCHONDRIAL ENCEPHALOMYOPATHIES; NEURAL CONDUCTION; PYRUVATE DEHYDROGENASE COMPLEX DEFICIENCY DISEASE;

EID: 40849131523     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2007-2062     Document Type: Article

References (15)

1. Stacpoole PW, Barnes CL, Hurbanis MD, Cannon SL, Kerr DS. Treatment of congenital lactic acidosis with dichloroacetate. Arch Dis Child. 1997;77(6):535-541
2. Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate as a treatment for MELAS: a randomized, controlled clinical trial. Neurology. 2006;66(3):324-330
3. Stacpoole PW, Kerr DS, Barnes C, et al. A controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics. 2006;117(5):1519-1521
4. Stickler D, Valenstein E, Neiberger RE, et al. Peripheral neuropathy in genetic mitochondrial diseases. Pediatr Neurology. 2006;34(2):127-131
5. Kaufmann P, Pascual JM, Anziska Y, et al. Nerve conduction abnormalities in patients with MELAS and the A3243G mutation. Arch Neurol. 2006;63(5):746-748
6. Felitsyn N, Stacpoole PW, Notterpek L. Dichloroacetate causes reversible demyelination in vitro: Potential mechanism for its neuropathic effect. J Neurochem 3007;100(2):429-436
7. Crnett R, James MO, Henderson GN, Cheung J, Shroads AL, Stacpoole PW. Inhibition of glutathione S-transferase zeta and tyrosine metabolism by dichloroaceate: a potential unifying mechanism for its altered biotransformation and toxicity. Biochem Biophys Res Commun. 1999;262(3):752-756
8. Langlois C, Jorquera R, Finegold M, Shroads AL, Stacpoole PW, Tanguay RM. Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1. Biochem Pharmacol. 2006;71(11):1648-1661
9. Felitsyn N, Stacpoole PW, Notterpek L. Delta-aminolevulinic acid inhibits myelination by Schwann cells. Presented at Neuroscience 2007, San Diego, CA, November 3-7, 2007
10. Stacpoole PW, Shroads AL, Felitsyn NM, Notterpek L, Calcutt NA. Mechanism of Age Dependence of Dichloroacetate- Induced Peripheral Neuropathy. Atlanta, GA: United Mitochondrial Disease Foundation; 2006:14-18
11. Curry SH, Chu PI, Baumgartner TG, Stacpoole PW. Plasma concentrations and metabolic effects of intravenous sodium dichloroacetate. Clin Pharmacol Ther. 1985;37(1):89-93
12. Stacpoole PW, Henderson GN, Yan Z, Cornett R, James MO. Pharmacokinetics, metabolism and toxicology of dichloroacetate. Drug Metab Rev. 1998;30(3):499-539
13. Ammini CV, Stacpoole PW. Biotransformation, toxicology and pharmacogenomics of dichloroacetate. In: Gribble GW, ed. Natural Production of Organohalogen Compounds. Vol. 3/P in the series The Handbook of Environmental Chemistry. Berlin, Springer-Verlag; 2003:215-234
14. Bonnet S, Archer SL, Allalunis-Turner J, et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 2007;11(1):37-51
15. Berendzen K, Theriaque D, Shuster J, Stacpoole, PW. Therapeutic potential of dichloroacetate for pyruvate dehydrogenase complex deficiency. Mitochondrion. 2006;6(3):126-135